These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 11171942)

  • 1. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.
    Strange PG
    Pharmacol Rev; 2001 Mar; 53(1):119-33. PubMed ID: 11171942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs.
    Lidow MS; Goldman-Rakic PS
    J Pharmacol Exp Ther; 1997 Nov; 283(2):939-46. PubMed ID: 9353417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
    Meltzer HY; Matsubara S; Lee JC
    Psychopharmacol Bull; 1989; 25(3):390-2. PubMed ID: 2576319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
    Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
    Rauser L; Savage JE; Meltzer HY; Roth BL
    J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
    Xu R; Hranilovic D; Fetsko LA; Bucan M; Wang Y
    Mol Psychiatry; 2002; 7(10):1075-82. PubMed ID: 12476322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in extracellular dopamine in the rat globus pallidus induced by typical and atypical antipsychotic drugs.
    Fuchs H; Hauber W
    Neurochem Int; 2004 Dec; 45(7):1029-38. PubMed ID: 15337302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.
    Wurch T; Boutet-Robinet EA; Palmier C; Colpaert FC; Pauwels PJ
    J Pharmacol Exp Ther; 2003 Jan; 304(1):380-90. PubMed ID: 12490615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonism and inverse agonism at dopamine D2-like receptors.
    Strange PG
    Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse agonist properties of atypical antipsychotic drugs.
    Akam E; Strange PG
    Biochem Pharmacol; 2004 Jun; 67(11):2039-45. PubMed ID: 15135301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The atypical neuroleptic concept].
    Azorin JM; Dassa D; Jalfre M
    Encephale; 1992 Sep; 18 Spec No 3():453-7. PubMed ID: 1364079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Receptor occupancy and antipsychotic drug action measured by PET and SPECT].
    Okubo Y; Suhara T
    Seishin Shinkeigaku Zasshi; 2001; 103(4):329-40. PubMed ID: 11392846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.